Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer

Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer

Several multigene assays have been developed to help clinicians in defining adjuvant treatment for patients with hormone-receptor-positive (HR+), human epidermal growth factor receptor-2 (HER2)–negative early breast cancer. Despite the 21-gene assay having been available for decades, it has only rec...

Full description

Bibliographic Details
Main Authors: Flavia Jacobs, Mariangela Gaudio, Chiara Benvenuti, Rita De Sanctis, Armando Santoro, Alberto Zambelli
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Cancers
Subjects:
genomic signature
OncotypeDX
precision medicine
HR-positive early breast cancer
adjuvant chemotherapy
clinicopathological factors
Online Access:https://www.mdpi.com/2072-6694/15/1/148

Similar Items

Similar Items